PF-Atlas › Clinical Trials › NCT00764309

Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

dasatinib · Phase 1

Registry ID
NCT00764309
Phase
Phase 1
Status
Completed
Drug / intervention
dasatinib
Sponsor
Bristol-Myers Squibb
Start
2009-01
Enrollment
47
Locations
13

About this trial

The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.

View NCT00764309 on ClinicalTrials.gov →

Explore related

Dasatinib + Quercetin — Treatment profileAll dasatinib trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT00764309 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.